Health

GN Hearing partners with hearing care professionals to launch a game-changing telehealth solution: New innovative at-home access to hearing aids and care

Thursday, April 2, 2020 - 9:39am

GN Hearing, the global leader in hearing aid technology, today announced the introduction of ReSound Assist Live, a real-time video-enabled hearing care service.

Key Points: 
  • GN Hearing, the global leader in hearing aid technology, today announced the introduction of ReSound Assist Live, a real-time video-enabled hearing care service.
  • With the launch of ReSound Assist Live, people can now have new hearing aids adjusted remotely by their hearing care professional via new at-home video consultations without physically going to a clinic.
  • Additionally, in these difficult times, hearing care professionals can provide new hearing aids for those who have recently completed a hearing test.
  • ReSound hearing aids, available from leading hearing care professionals, have set worldwide standards for quality and intuitive technology.

How to Implement Social Distancing Practices in Your Workplace

Thursday, April 2, 2020 - 8:00am

This quick guide showcases essential distancing supplies and illustrates steps to take to incorporate the concept of social distancing in your facility.

Key Points: 
  • This quick guide showcases essential distancing supplies and illustrates steps to take to incorporate the concept of social distancing in your facility.
  • Also known as "physical distancing," social distancing is the practice of staying six feet away from other people and avoiding person-to-person contact in order to prevent the spread of respiratory illness.
  • Wall signs that remind people to wash their hands and keep their distance are also great tools to encourage mindful social distancing.
  • Creative Safety Supply's downloadable quick guide shows you how you can implement social distancing in your business by providing helpful tools and steps.

BrainTale Announces CE Marking of Its First Product for Brain Quantitative Measurement, brainQuant, And Its ISO:13485:2016 Certification

Thursday, April 2, 2020 - 8:00am

The company received ISO 13485:2016 certification, an international standard governing the requirements of a quality management system for medical devices and related company services.

Key Points: 
  • The company received ISO 13485:2016 certification, an international standard governing the requirements of a quality management system for medical devices and related company services.
  • The CE marking Conformite Europeenne certifies that the product meets European Union (EU) requirements for marketing in Europe.
  • BrainTale develops and commercializes accessible, effective and clinically-validated measurement and prognosis tools for brain injured patients.
  • This news is a major achievement allowing healthcare professionals to use our first product in compliance with EU requirements.

SETi’s Violeds Technology Proves 99.9% Sterilization of Coronavirus (COVID-19) in 30 Seconds

Thursday, April 2, 2020 - 7:53am

Sensor Electronic Technology, Inc. (SETi), a leading global innovator of deep UV LED products and technology, announced that it has been successful in achieving 99.9% sterilization of coronavirus (COVID-19) in 30 seconds.

Key Points: 
  • Sensor Electronic Technology, Inc. (SETi), a leading global innovator of deep UV LED products and technology, announced that it has been successful in achieving 99.9% sterilization of coronavirus (COVID-19) in 30 seconds.
  • In the study by SETi and Seoul Viosys, Violeds technology is used to show just how strong the sterilization effect can be on COVID-19 when exposed to Violeds photons for 30 seconds.
  • The study also finds the coronavirus becomes even more sterile when placed closer to the photon with longer exposure time.
  • Violeds, compound semiconductor technology, is the brand name of technology that utilizes UV LED for sterilization and deodorization functions.

RELIEF THERAPEUTICS Holding SA Announces the Closing of its Share Exchange Agreement with Sonnet BioTherapeutics, Inc. for the Divestment of its wholly-owned Subsidiary Relief Therapeutics SA

Thursday, April 2, 2020 - 7:16am

RELIEF THERAPEUTICS Holding SA (SIX:RLF, "Relief Holding") announces today the closing of the binding Share Exchange Agreement (SEA) for the acquisition by Sonnet BioTherapeutics, Inc. (Sonnet), now a subsidiary of Sonnet BioTherapeutics Holdings, Inc. (formerly known as Chanticleer Holdings, Inc.) (Nasdaq:SONN, "Sonnet Holdings") of Relief Therapeutics SA (Relief SA), a subsidiary of Relief Holding signed August 12, 2019.

Key Points: 
  • RELIEF THERAPEUTICS Holding SA (SIX:RLF, "Relief Holding") announces today the closing of the binding Share Exchange Agreement (SEA) for the acquisition by Sonnet BioTherapeutics, Inc. (Sonnet), now a subsidiary of Sonnet BioTherapeutics Holdings, Inc. (formerly known as Chanticleer Holdings, Inc.) (Nasdaq:SONN, "Sonnet Holdings") of Relief Therapeutics SA (Relief SA), a subsidiary of Relief Holding signed August 12, 2019.
  • As a consequence, Sonnet acquires all outstanding shares of Relief SA that becomes a wholly-owned Geneva-based subsidiary of Sonnet.
  • In counterpart, Sonnet paid to Relief Holding shares of its common stock that converted into 757,933 shares of listed Sonnet Holdings common stock.
  • This divestment will allow Relief Holding to focus its resources to further develop its main asset Aviptadil for pulmonary affections.

NOXXON Announces Completion of Patient Recruitment for the First Dose Cohort in the Phase 1/2 Brain Cancer Study Of NOX-A12 Plus Radiotherapy

Thursday, April 2, 2020 - 7:00am

The study investigates three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external-beam radiotherapy in newly diagnosed brain cancer patients in a Phase 1/2 clinical trial.

Key Points: 
  • The study investigates three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external-beam radiotherapy in newly diagnosed brain cancer patients in a Phase 1/2 clinical trial.
  • Under the approved protocol, it is planned that each patient is treated with NOX-A12 for up to six months.
  • The combination of NOX-A12 and radiotherapy has so far been well-tolerated by the patients that participated in this clinical trial.
  • In September 2019 the company initiated an additional trial with NOX-A12 in brain cancer in combination with radiotherapy.

AAGL to Host LIVE Webinar on Safe Gynecologic Surgery During the COVID-19 Pandemic

Thursday, April 2, 2020 - 6:00am

"This webinar is slated to be an engaging and informative discussion from leading surgeons on the frontlines of the COVID pandemic."

Key Points: 
  • "This webinar is slated to be an engaging and informative discussion from leading surgeons on the frontlines of the COVID pandemic."
  • -Jubilee Brown, MD, AAGL President
    This webinar training will be available live on AAGL's Online Video Platform, SurgeryU.
  • AAGL is a professional medical association of laparoscopic surgeons and is the global leader in minimally invasive gynecologic surgery.
  • The AAGL is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Revolutionary DocTalkGo Telehealth Company Offers Remote Medical Services for COVID-19 Patients

Thursday, April 2, 2020 - 6:00am

Any and all patients with symptoms of the coronavirus must seek a medical professional who can determine whether or not a patient receives a COVID-19 test.

Key Points: 
  • Any and all patients with symptoms of the coronavirus must seek a medical professional who can determine whether or not a patient receives a COVID-19 test.
  • While testing becomes increasingly accessible, many states still struggle to provide adequate and consistent testing for patients.
  • DocTalkGo, a leader in the telehealth industry offering remote based medical services for patients across the U.S., is able to identify individuals with non-acute COVID-19 or influenza symptoms and provide at-home testing .
  • Chief medical officer of DocTalkGo says that may be much easier and safer for patients to make a telemedicine appointment where a doctor can evaluate whether you might qualify for COVID-19 testing.

Sensorion Reports Full-year 2019 Financial Results and Business Update

Thursday, April 2, 2020 - 6:30am

As part of this consortium, Sensorion will receive up to 5.6 million over the duration of the project contingent on milestones completion.

Key Points: 
  • As part of this consortium, Sensorion will receive up to 5.6 million over the duration of the project contingent on milestones completion.
  • SENS-111 (Seliforant) was safe and well tolerated in a Phase 2 proof-of-concept study for the treatment of acute unilateral vestibulopathy (AUV).
  • However, it did not meet the primary endpoint of vertigo intensity and Sensorion stopped all development activities for SENS-111.
  • On the 13th of March, Sensorion made an update on timelines for the ongoing Phase 2 study of SENS-401 to treat Sudden Sensorineural Hearing Loss (SSNHL).

Crossroads Treatment Centers Pioneers TeleVisits to Continue Seeing Patients During COVID-19 Crisis

Thursday, April 2, 2020 - 6:00am

Crossroads Treatment Centers , a category leader in outpatient treatment of Opioid Use Disorder, announced today that it will offer TeleVisit appointments throughout all of its Office-Based Opioid Treatment (OBOT) centers in Kentucky, New Jersey, Pennsylvania, and Virginia.

Key Points: 
  • Crossroads Treatment Centers , a category leader in outpatient treatment of Opioid Use Disorder, announced today that it will offer TeleVisit appointments throughout all of its Office-Based Opioid Treatment (OBOT) centers in Kentucky, New Jersey, Pennsylvania, and Virginia.
  • Crossroads is working on expanding TeleVisits to include counseling and toxicology, ensuring a comprehensive recovery program for its patients.
  • Maintaining access is a critical component of success for patients recovering from opioid addiction, said Trey Causey, M.D., Chief Medical Officer at Crossroads Treatment Centers.
  • Headquartered in Greenville, S.C., Crossroads Treatment Centers is a national leader in outpatient treatment for Opioid Use Disorder, operating over 90 addiction treatment facilities across 10 states.